medigraphic.com
ISSN 0016-3813 (Print)

2001, Number 3

<< Back Next >>

Gac Med Mex 2001; 137 (3)

Safety and Efficacy of Echogen. A Study with Transthoracic Echocardiography

Espinola-Zavaleta N, Yánac-Chávez P, Vargas-Barrón J, Romero-Cárdenas A, Roldán-Gómez J

Language: Spanish
References: 26
Page: 203-208
PDF size: 57.65 Kb.


ABSTRACT

This study was performed to determine the safety and efficacy of intravenous dodecafluoropentane emulsion (Echo Gen), to determine the efficacy and duration of contrast agent in left cavities by transthoracic echocardiography and to evaluate the clinical impact of Echogent. Fifteen patients were studied. by transthoracic echocardiography. Duration of contrast intensity of left ventricular cavity opacification and endocardial border definition were studied. The adverse effects were assessed immediately, 24 hours and 7 days after Echogen. Both the vital signs and electrocardiogram did not show any significant changes. Minimal changes in hepatic function in one patient and in renal function in other one were observed. The mean duration of left ventricular opacification was 4 minutes 47 seconds and full or intermediate opacification was more frequently observed after Echogen. Endocardial border delineation was poor in one patient, intermediate in five and excellent in nine.In 86.7% the diagnostic information obtained was sufficiently and allowed other studies. Conclusions. This study demonstrates that Echogen is effective for Left ventricular cavity opacification, endocardial border definition and assessment of left ventricular volumen and ejection fraction 2) The obtained information with the use of Echogen allowed other studies. 3) The intravenous administration of Ecehogen is safe in doses of 0.05ml/Kg,


REFERENCES

  1. Edler I. Diagnostic use of ultrasound in Heart disease. Acta Med Scand 1955;32:308.

  2. Wells PNT. Biomedical Ultrasonic. New York; Academic Press. 1977.

  3. Fry FJ (ed.). Intense focused ultrasound. In ultrasound: Its Applications in Medicine and biology. Amsterdam, Elsevier Science Publishing, 1978.

  4. Krumholz HM, Douglas PS, Goldman L, Waksmonski C. Clinical utility of transthoracic two-dimensional and Doppler echocardiography. J Am Coll Cardiol 1994;24:125-131.

  5. Freeman AP, Giles RW, Walsh WF, Fisher R, Murray IPC, Wilcken DEL. Regional left ventricular wall motion assessment: comparison of two-dimensional echocardiography and radionuclide angiography in healed myocardial infarction Am J Cardiol 1985;56:8-12.

  6. Vannan MA. Myocardial contrast echocardiography: current status and potential clinical applications. VIII World Congress of Ultrasound in Medicine and Biology 1997;6-7.

  7. Zotz RJ, Genth S, Waaler A, Erbel R, Meyer J. Left ventricular volume determination using Albunex J Am Soc Echocardiogr (abstract). J Am Coll Cardiol 1996;9;1-8.

  8. Hundley WG, Kizilbash A, Afridi I, Franco F, Peshock RM, Grayburn PA. Intravenous dodecafluoronentane improves determination left ventricular function during transthoracic echocardiography (abstract). J Am Coll Cardiol 1997;29 suppl A:520A

  9. Feinstein SB, Cheirif J, Tencate FJ. Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicentric clinical results. J Am Coll Cardiol 1990;16:316- 324.

  10. Crouse LJ, cheirif J, hanly DE. Opacification and border delineation improvement in patients with suboptimal endocardial border definition in routine echocardiography. Results of the phase III. Multicenter trial. J Am Coll Cardiol 1993;22:1494-1500.

  11. Cotter B, Kwan O, Kimura B. Evaluation of the efficacy. safety arid and pharmacokinetics of QW3600 (Echogen) in man (abstract). Circulation 1994;90 Suppl 1:1-2987.

  12. Cheitlin MD, Alpert JS, Amstrong WF. ACC/AHA guidelines for the clinical application of echocardiography: a report of the American College of cardilogy/American Heart Association Task force in Practice Guidelines (Committe on clinical application of echocardiography). Circulation 1997;95:1686-1744.

  13. Waggoner AD, Barzilai B, Perez JE. saline contrast enhancement of thicuspid regurgitation jets detected by Doppler color flow imaging. Am J Cardiol 1990;65:1368-1371.

  14. Becher H, Schlief R. Improved sensitivity. of color Doppler by SHU 454. Am J Cardiol 1989;64:374-377. .

  15. 15 Block U, Brodsky L, Ostoic T. Optimizing Albunex in the left ventricle: an analysis of the technical parameters of four ultrasound systems in canines and humans. J Am Soc Echocardiogr 1996;9:787-794.

  16. Vuille C, Nidorf M, Morrissey RL, Newell JB, Weyman AE, Picard MH. Effect of static pressure on the disappearance rate of specific echocardiographic contrast agents. J Am Soc Ecnocardiogr 1994;7:347-354.

  17. Wei K, Skyba DM, Firschke C, Lindner JR, Jayaweera AR, Kaul S. interation between microbubbles and ultrasound: in vitro and in vivo observation. J Am Coll Cardiol 1997;29: 1081-1088.

  18. Grayburn PA, Erickson JF, Womack L, Velasco CE. Peripheral intravenous myocardial contrast echocardiography using 2% dodecafluoropentane emulsion: identification of myocardial risk area and infract size in canine model of ischemia. J Am Coll Cardiol 1995;26: 1340-1347.

  19. Santoro GW, Valenti R, Buonamici P, Bolognese L, Cerisano G, Moschi G, Trapani M, Antoniucci D, Fazzini PF. Relation between ST-segment changes and myocardial perfusion evaluated by myocardial contrast echocardiography in patients with acute myocardial infarction treated with direct angioplasty. Am J Cardiol 1998;82:932-937. .

  20. 20 Schlief R, Staks T, Mahler M, Rufer M, Fritzsch T, Seifert W. Successful opacification of the left heart chambers on echocardiographic examination after intravenous injection of a new saccharide based contrast agent. Echocardiography 1990;7:61-64.

  21. Von Bibra H, Sutherland G, Becher H, Neudert J, Nihoyannopoulos P. Clinical evaluation of left heart Doppler contrast enhancement by a Saccharide-based Transpulmonary contrast agent. J Am Coll Cardiol 1995;25:500-508.

  22. Crouse L, Cheirif J, Kisslo JA, Labovitz AJ, Raichlen JS; Schutz RW, Shah PM, Smith MD. Opacification and border delineation improvement in patients with suboptimal endocardial border definition on routine echocardiography results of a phase III Albunex* multicentertrial. J Am Coll Cardiol 1991;17 (Suppl):348A.

  23. Meltzer RS, Tickner EG, Sahines TP, Popp RL. The sources ultrasound contrast effect. J Clin Ultrasound 1980;(:121-126.

  24. Berwing K, Schlepper M. Echocardiographic imaging of the left ventricle in peripheral intravenous injection of echo contrast agent. Am heart J 1988;115:399-408.

  25. EchoGen Emulsion Scientific Abstracts. An investigational product monograph of publish academic studies. Sonus Pharmaceuticals Inc. April 1996.

  26. Grayburn PA, Weiss JL, Hack TC, Klodas E, Raichien JS, Vannan MA et al. Phase III multicenter trial comparing the efficacy of 2% dodecafluoropentane emulsion (EchoGen) and sonicated 5% human albumin (albunex) as ultrasound contrast agents in patients with suoptimal echocardiograms. J Am Coll Cardiol 1998;32:230-236.




2020     |     www.medigraphic.com